Skip to content
Search AI Powered

Latest Stories

Military Invests in MDMA for PTSD Treatment

In a historic shift, the Department of Defense is funding two major clinical trials—totaling $9.8 million—to study the use of MDMA-assisted therapy for treating PTSD in active-duty service members. The research marks the first sanctioned exploration of psychedelics within the military. While the move signals progress, broader access to alternative therapies like cannabis and psilocybin remains blocked—leaving many veterans still fighting for healing options the government won’t yet fund.

the pentagon, washington dc, aerial view

The Pentagon Is Betting Nearly $10 Million on MDMA to Treat PTSD in Active-Duty Soldiers

The U.S. Department of Defense (DoD) has earmarked $9.8 million for pioneering research into the therapeutic potential of psychedelics, specifically MDMA, for active-duty service members grappling with post-traumatic stress disorder (PTSD). This initiative underscores a significant shift in military mental health strategies, acknowledging the pressing need for innovative treatments amid rising concerns over service members' well-being.Latest news & breaking headlines+1Military Times+1

Breaking Down the Investment


The funding is divided into two equal grants of $4.9 million:Military Times

  • Walter Reed National Military Medical Center: Set to conduct a double-blind, placebo-controlled trial, this study will administer MDMA to active-duty Army personnel diagnosed with mild to moderate PTSD. The primary objective is to assess how MDMA influences psychological flexibility, a key factor in effective PTSD treatment. Leading this research is Major Aaron Wolfgang, head of Inpatient Psychiatry at Walter Reed, who has previously contributed to comprehensive reviews on MDMA-assisted therapy. Military Times+1Latest news & breaking headlines+1
  • Emory University and STRONG STAR Consortium: Collaborating with the University of Texas Health Science Center at San Antonio, this partnership will explore MDMA-assisted therapy's efficacy in treating PTSD among active-duty troops. STRONG STAR is renowned for its focus on combat-related PTSD research, making it a pivotal player in this groundbreaking study.

A Historical Perspective

This endeavor marks the first sanctioned investigation into MDMA's therapeutic applications for PTSD within active-duty military personnel. Historically, the U.S. government's engagement with psychedelics in military contexts has been controversial, often associated with unauthorized experiments during the mid-20th century. This contemporary research signifies a departure from past practices, emphasizing scientific rigor and ethical standards.

The Broader Context: Veterans and Alternative Therapies

While the DoD's commitment to exploring psychedelics is a progressive step, it occurs against a backdrop of governmental resistance to alternative treatments for veterans. Efforts to expand access to cannabis and psychedelics for medical purposes have faced legislative hurdles. For instance, amendments proposing research into psilocybin and MDMA for PTSD and traumatic brain injury were recently rejected, leaving many veterans without access to potentially life-changing therapies.

FDA Approves Landmark Cannabis for PTSD in Veterans - The BluntnessFDA Approves Landmark Cannabis for PTSD in Veterans - The Bluntness Photo by Wesley Tingey on Unsplash

The Imperative for Innovative Solutions

The urgency for effective mental health interventions in the military community cannot be overstated. Studies have shown that women veterans are 1.8 times more likely than their civilian counterparts to commit suicide, highlighting the critical need for comprehensive and effective treatment options.

The DoD's $9.8 million investment in psychedelic research represents a hopeful development in addressing the complex mental health challenges faced by service members. As these studies progress, they hold the potential to reshape treatment paradigms and offer new avenues for healing to those who have served.

More For You

gif of actor Kevin James from King of Queens; asking "How Much Does That Cost?"
Why Is Some Weed More Expensive Than Others? Understanding Cannabis Pricing
Giphy

Unraveling Cannabis Pricing: Factors Behind the Cost of Weed


Step inside a cannabis dispensary for the first time and the experience can be overwhelming. The meticulously labeled glass jars showcase dozens of strains with names like "Wedding Cake" and "Blue Dream," while refrigerated cases display concentrates, edibles, and tinctures at wildly different price points. Unlike the days when consumers were limited to whatever their neighborhood dealer offered, today's legal market presents a dazzling array of options that might leave newcomers with both wonder and sticker shock.

Keep ReadingShow less
Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Photo by Axel Antas-Bergkvist on Unsplash

Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness

Kanye West, aka Ye, isn’t just trending—he’s unraveling in real time. And instead of intervention, we get viral clips, condemnation, and an audience watching a man self-destruct. His latest stunt? Airing a Super Bowl ad promoting a swastika-emblazoned Yeezy shirt on his site—a move so blatantly antisemitic that even the most die-hard supporters had to step back. This act garnered significant media coverage, leading to brands cutting ties and agents dropping him. His social media account faced scrutiny and was ultimately deleted after a history of controversial postings. But here’s the problem: canceling Kanye doesn’t fix Kanye.

At this point, the question isn’t whether his actions are inexcusable (they are). The question is, what happens when one of the world’s most influential figures is also one of the most untreated cases of mental illness in pop culture history?

Keep ReadingShow less
Cannabis Industry in Crisis According to New Research
Cannabis Industry in Crisis According to New Research

Cannabis Industry in Crisis According to New Research

Whitney Economics, a prominent cannabis economics data, consulting, and research firm, has recently released its second annual Cannabis Operator Sentiment and Business Conditions survey report. The report, based on an extensive survey of U.S. cannabis business licensees, examines the perspectives of industry operators on their success and the barriers they face.

The survey assessed shortages and surpluses in materials, services, and labor inputs in relation to future expectations. It also revealed key business metrics such as revenues, profits, margins, and costs.

Keep ReadingShow less
Actor/Comedian Awkwafina smoking a joint held with chopsticks
Getting high w/ Awkwafina
Giphy

4/20: The Evolution of a Cultural Phenomenon


From countercultural whisper to mainstream celebration, the journey of April 20th—known simply as “4/20”—represents one of the most fascinating cultural shifts of our time. A decade ago, large gatherings at places like the University of Colorado Boulder were common, but administrative bans have since changed the landscape of 4/20 celebrations significantly. What began as coded communication among a small group of California teenagers has transformed into a global phenomenon that transcends its origins, reshaping attitudes, commerce, and policy along the way. While most things die within a couple years, '420' has persisted and grown in popularity, highlighting its sustained relevance and cultural significance among cannabis enthusiasts.

Keep ReadingShow less
image of California coast, pacific coast highway at sunset
How Overregulation Crushed California’s Gold Flora—And Why Other States Should Be Worried
Photo by Matthew Hamilton on Unsplash

Overregulation Kills Gold Flora

When California-based Gold Flora entered the legal cannabis scene, the company was poised to dominate. Backed by serious money and a sprawling, vertically integrated operation—from a 100,000-square-foot cultivation campus in the desert to marquee dispensaries in West Hollywood and San Jose—Gold Flora wasn't just riding the green wave. It was supposed to be the wave.

But by the end of March 2025, the company had filed for receivership, its assets now headed to auction. And while headlines cite "merger woes" and "market conditions," the real culprit behind Gold Flora’s collapse is far more systemic: a regulatory stranglehold that has quietly choked the life out of California’s once-promising cannabis economy.

Keep ReadingShow less